IndustryCompany release

ICU Medical lifts third-quarter revenue to $560.4M and reaffirms 2026 guidance

🇺🇸 Icu Medical Inc/De (ICUI) · Thu 05 Nov 2026

The infusion-therapy company reported a swing to GAAP profit and a wider gross margin, and expects to finish 2026 toward the high end of its guidance.

ICU Medical (Nasdaq: ICUI) reported results for the quarter ended 30 September 2026 on 5 November. Revenue rose to $560.4M, up from $537.0M in the same quarter a year earlier.

The company recorded GAAP net income of $26.8M, compared with a net loss in the prior-year quarter. Gross margin improved to 42%, from 37% a year earlier.

ICU Medical reaffirmed its full-year 2026 guidance, which includes adjusted EBITDA of $415M-$435M. It said it expects to finish toward the high end of that range.

The company's original release was not available for review, so further detail on segment performance, product lines or the drivers of the margin improvement is not covered here.

What it means for your team

  • Market-access and supply teams can note that ICU Medical has reaffirmed its 2026 guidance, with results expected toward the high end of the range.
  • The improved gross margin (42% versus 37%) and return to GAAP profit are financial indicators only; the available information does not describe any change in product supply or quality status.
  • Teams wanting segment-level or operational detail should consult the company's full earnings release and filings.

Company's press release (SEC filing): Icu Medical Inc/De ↗

Article written by VigiEye from the official source (Icu Medical Inc/De). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →